EU In Vitro Diagnostic Medical Devices Regulation (Regulation (EU) 2017/746)

What EU IVDR Is

Regulation (EU) 2017/746, the In Vitro Diagnostic Medical Devices Regulation (IVDR), governs diagnostic tests and the software that analyzes specimens taken from the human body, such as blood, tissue, and other samples. It replaced the older In Vitro Diagnostic Directive to strengthen clinical and analytical evidence, traceability, and oversight. IVDR introduced a new risk-based classification (Classes A to D) that places far more IVD products under Notified Body scrutiny than before.

Diagnostic software, including algorithms that interpret laboratory results or drive companion diagnostics, frequently falls within scope.

Who It Applies To

IVDR applies to manufacturers, authorized representatives, importers, and distributors placing in-vitro diagnostic devices on the EU market. It covers reagents, instruments, software, and systems intended for diagnostic use, including high-risk companion diagnostics and self-testing devices. Laboratories developing in-house tests may also face specific obligations under defined conditions.

Key Requirements

• Classification — Assign Class A, B, C, or D based on individual and public health risk.
• Performance evaluation — Demonstrate scientific validity, analytical performance, and clinical performance.
• Conformity assessment — Involve a Notified Body for most classes and apply CE marking.
• Technical documentation — Maintain detailed design, validation, and risk records.
• Post-market surveillance — Operate vigilance reporting and post-market performance follow-up.
• UDI and EUDAMED — Assign unique device identifiers and register devices and economic operators.
• Risk management — Apply continuous risk management throughout the lifecycle.

Penalties for Non-Compliance

Member states set penalties, which may include fines, market withdrawal, recalls, and suspension or revocation of CE certificates. Placing non-conforming diagnostics on the market exposes manufacturers to enforcement, liability for harm, and exclusion from the EU market when certification is lost.

How to Comply

Classify devices accurately and plan early for the heavier evidence burden under higher classes. Establish a quality management system, generate robust performance evaluation evidence covering scientific validity and analytical and clinical performance, and engage Notified Bodies where required. Implement UDI, register in EUDAMED, and operate active post-market surveillance with performance follow-up. Manage software changes carefully, since updates can affect classification and require reassessment.